Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

and taking the supplement before a meal is key to feeling your best. Over 1,000 shoppers have purchased the supplement this ...

In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Lexaria Bioscience (LEXX) has received lead clinical site human research ethics committee approval that was required before dosing can begin in ...

The Study will also include use of certain glucagon-like peptide-1 ("GLP-1") receptor specific antibodies detectable ... Such forward-looking statements are estimates reflecting the Company's best ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Glucagon-like peptide medications that treat Type 2 diabetes and weight management continue to grow in popularity, though ...

"Holding GLP-1 receptor agonists may not be as protective ... A clear liquid diet may be the best way to ensure an empty stomach." He said more data on total patients, types of GLP-1s used ...